fig1

Figure 1. NID1 is highly expressed in HCC patients and promotes DC maturation. (A) The TIMER3.0 database shows NID1 expression in liver cancer and normal tissues, as well as its prognostic impact on patients with liver cancer; (B) Analysis of the relationship between NID1 and mDC infiltration in liver cancer tissues using the TIMER3.0 database; (C) The TIMER3.0 database shows a correlation between NID1 and Treg infiltration in liver cancer, with their combined impact on patient survival; (D) Western blot of NID1 expression in 1753^p53-/-cmyc and Hepa1-6 cells; (E) Gating strategy for flow cytometry analysis of the expression changes in BMDC maturation markers; (F) Flow cytometry analysis of changes in expression of CD80, CD86, and CD40 in BMDCs after co-culture with 1753^p53-/-cmyc and Hepa1-6 cells using a Transwell system. Data are presented as mean ± SD, with statistical significance determined by one-way ANOVA (Tukey’s test). Biological replicates are represented as individual data points. Western blot analysis was performed with three biological replicates. ^*P < 0.05; ^**P < 0.01, ^****P < 0.0001. NID1: Nidogen 1; HCC: hepatocellular carcinoma; DC: dendritic cell; mDC: myeloid dendritic cell; Treg: regulatory T cell; FOXP3: forkhead box protein P3; TPM: transcripts per million; HR: hazard ratio; BMDC: bone marrow-derived dendritic cell; TIMER3.0: Tumor Immune Estimation Resource 3.0; LIHC: liver hepatocellular carcinoma; MCPCOUNTER: Microenvironment Cell Populations-counter; QUANTISEQ: quantitative immune cell deconvolution method; FSC-A: forward scatter-area; FSC-H: forward scatter-height; SSC-A: side scatter-area; CD11c: cluster of differentiation 11c; CD80: cluster of differentiation 80; CD86: cluster of differentiation 86; CD40: cluster of differentiation 40; L/D: live/dead viability dye; SD: standard deviation; ANOVA: analysis of variance.